- Home
- CVM vs TVRD Comparison
CVM vs TVRD Comparison
Compare CVM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVM | TVRD |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 36.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVM | TVRD |
|---|---|---|
| Price | $4.36 | $3.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 38.0K | ★ 50.8K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,033.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.23 | $2.75 |
| 52 Week High | $13.48 | $43.65 |
Technical Indicators
Market Signals| Indicator | CVM | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 43.46 |
| Support Level | $4.01 | $2.75 |
| Resistance Level | $4.73 | $4.45 |
| Average True Range (ATR) | 0.38 | 0.21 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 70.93 | 53.15 |
Price Performance
Historical ComparisonAbout CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.